CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Execution Version: 29/06/16 EXCLUSIVE LICENSE AGREEMENT by and between...Exclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations • London
This Agreement ("Agreement"), effective as of June 29, 2016 ("Effective Date"), is entered into by and between Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli corporation with its principal office at Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390 Israel ("YISSUM"), and Edesa Biotech Inc., an Ontario corporation with its principal office at I 00 Spy Court, Markham, Ontario, L3R 5H6 ("EDESA"). YISSUM and EDESA may be referred to herein individually as a "Party" or collectively as the "Parties". Reference to a Party shall be deemed to include that Patty's Affiliates.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations
This First Amendment ("First Amendment"), effective as of April 3, 2017 ("Effective Date"), is entered into by and between Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli corporation with its principal office at Hi-Tech Park, Edmond
LEASE (COMMERCIAL)Lease Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations
In consideration of the rents, covenants and obligations stipulated herein the Landlord and the Tenant have agreed to enter into a lease of certain offices in the building (the "Building") located at 100 Spy Court, Markham, ON, consisting of approximately 2,800 square feet as more particularly shown on Schedule "A"
EXCLUSIVE LICENSE AGREEMENT by and between CIPHER PHARMACEUTICALS INC. and EDESA BIOTECH INC. June 15, 2016Exclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations • Ontario
This Agreement (the "Agreement"), effective as of June 15, 2016 (the "Effective Date"), is entered into by and between Cipher Pharmaceuticals Inc., an Ontario corporation with its principal office at 2345 Argentia Road, Suite 100A, Mississauga, Ontario, L5N 8K4 ("Cipher"), and Edesa Biotech Inc., an Ontario corporation with its principal office at 100 Spy Court, Markham, Ontario, L3R 5H6 ("Licensee"). Cipher and Licensee may be referred to herein individually as a "Party" or collectively as the "Parties". Reference to a Paity shall be deemed to include that Party's Affiliates.
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations • Quebec
This License and Development Agreement ("Agreement") is made effective as of [date] ("Effective Date") by and between Pendopharm, a division of Pharmascience Inc, located at 6111 Royalmount, Suite 100, Montreal, Quebec, H4P 2T4, Canada (hereinafter "Pendopharm"), and Edesa Biotech Inc., a Canadian corporation having its principal place of business at 100 Spy Court Markham, Ontario, L3R 5H6, Canada (hereinafter "Edesa").
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 30th, 2019 • Edesa Biotech, Inc. • Pharmaceutical preparations
This Second Amendment ("Second Amendment"), effective as of May 7, 2017 ("Effective Date"), is entered into by and between Yissum Research Development Company of the Hebrew University of Jerusalem, an Israeli corporation with its principal office at Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem P.O. Box 39135, Jerusalem 91390 Israel ("YISSUM"), and Edesa Biotech Inc., an Ontario corporation with its principal office at 100 Spy Court, Markham, Ontario, L3R 5H6 ("EDESA"). YISSUM and EDESA may be referred to herein individually as a "Party" or collectively as the "Parties". Reference to a Party shall be deemed to include that Party's Affiliates.
